Cipla has announced that the United States Food and Drug Administration (USFDA) has classified its recent inspection at the company’s manufacturing facility in Bommasandra, Bengaluru, as Voluntary Action Indicated (VAI).
The inspection, which took place from May 26 to May 30, 2025, was conducted to evaluate the facility’s adherence to current Good Manufacturing Practices (cGMP). In a formal email communication received on August 4, 2025 (23:59 IST), the USFDA confirmed the VAI classification.
A VAI status typically indicates that inspectors identified certain issues during the audit, but none of them were serious enough to warrant official regulatory action. It implies that the company may need to take voluntary corrective steps, though it can continue production and distribution.
This update follows Cipla’s earlier intimation dated May 30, 2025, about the USFDA inspection. The company has assured stakeholders that it will work diligently to address any observations noted by the agency.
